Captor Therapeutics Spolka Akcyjna Profit Margin

The latest profit margin for CTX.WA is -2207.63% as of June 2026. That compares with -355.64% in the prior-year period — down 520.7% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Captor Therapeutics Spolka Akcyjna's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTX.WA's profit margin moved from -355.64% to -2207.63% — a 520.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Captor Therapeutics Spolka Akcyjna's valuation or profitability profile.

Against Healthcare companies, CTX.WA currently prints -2207.63% for profit margin, while the sector average sits near 9.48%. That is roughly 23384.8% below the sector mean. Large gaps often invite a closer look at Captor Therapeutics Spolka Akcyjna's growth, margins, and balance sheet.

Profit Margin shows how effectively Captor Therapeutics Spolka Akcyjna converts resources into returns. At -2207.63%, CTX.WA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -355.64% in the prior-year period — down 520.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CTX.WA's profit margin (-2207.63%), review year-over-year change from -355.64%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.